The impact of SGLT2i on the outcome of advanced lung cancer in patients with diabetes [0.03%]
SGLT2i对糖尿病伴晚期肺癌患者预后的影响
Jindong Chen,Hao Wang,Conghui Shang et al.
Jindong Chen et al.
Objective: Sodium-glucose cotransporter-2 inhibitors (SGLT2i), a novel pharmacological agent for diabetes and heart failure, may influence oncologic outcomes. Their role in advanced lung cancer patients with diabetes is u...
A CT-based radiomics model for preoperative risk stratification of gastrointestinal stromal tumors [0.03%]
基于CT的影像组学模型在胃肠道间质瘤术前风险分层中的应用
Tianyi Wan,Yanping Song,Xiaolian Wang et al.
Tianyi Wan et al.
Background: Gastrointestinal stromal tumors (GISTs) are common mesenchymal tumors with variable malignancy potential, making accurate preoperative risk stratification crucial for treatment planning. Traditional methods re...
Case Report: Surgical resection combined with chemotherapy for a primary cardiac lymphoma involving right heart structures [0.03%]
病例报告：手术切除联合化疗治疗侵犯右心结构的原发性心脏淋巴瘤
Wei Zhu,Xinying Ren,Hanrui Xiong et al.
Wei Zhu et al.
Primary cardiac lymphoma is a highly rare type of malignant tumor that originates from the lymphoid tissue within the heart or pericardium. Surgical treatment is the primary method for obtaining pathological results and relieving obstructio...
Commentary: Novel mtDNA methylation-associated prognostic signatures in colorectal cancer [0.03%]
评论：结直肠癌中新型线粒体DNA甲基化相关预后标志物
Xin Jiang,Xu Zhang,Maonan Wang
Xin Jiang
Correction: Preoperative inflammation-based immune prognostic nomogram in bladder cancer: a multicenter study [0.03%]
膀胱癌术前免疫预后预测模型的构建及多中心验证校正发表错误
Runlin Feng,Jian Zhang,Yanping Tao et al.
Runlin Feng et al.
[This corrects the article DOI: 10.3389/fonc.2025.1644747.]. Keywords: NLR; bladder cancer; immune microenvi...
Published Erratum
Frontiers in oncology. 2026 Feb 20:16:1787982. DOI:10.3389/fonc.2026.1787982 2026
Advances in intratumoral immunotherapy from a neuro-immune-endocrine perspective for breast cancer treatment [0.03%]
从神经-免疫-内分泌角度探究乳腺癌瘤内免疫治疗新进展
Claudia Angélica Garay-Canales,Mariana Segovia-Mendoza,Yair Rodríguez-Santiago et al.
Claudia Angélica Garay-Canales et al.
The incidence rate of breast cancer continues to grow worldwide and is increasingly occurring in younger women. Although treatments have improved, they present several distinct challenges, as life-threatening side effects, relapse, metastas...
The STAT3-ZEB1 axis contributes to CCL2-mediated resistance to osimertinib in lung cancer [0.03%]
STAT3-ZEB1轴介导的CCL2导致非小细胞肺癌对奥希替尼产生耐药性
Tzu-Hua Chang,Meng-Feng Tsai,Shang-Gin Wu et al.
Tzu-Hua Chang et al.
Objective: Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI), is effective in NSCLC patients with EGFR-activating or T790M mutations, but acquired resistance remains a major challenge. Although CCL2 has...
Ectopic adrenal nodular hyperplasia mimicking right upper polar renal cell carcinoma: a case report and literature review [0.03%]
异位肾上腺结节增生误诊为右肾上极肾细胞癌一例及相关文献复习
Shuxin Li,Yongliang Qu,Yongshuai Huang et al.
Shuxin Li et al.
Ectopic adrenal tissue refers to adrenal tissue appearing in an abnormal anatomical location, typically originating from residual adrenal tissue or ectopic structures during embryonic development. As a rare congenital anomaly, its atypical ...
Watch-and-Wait strategy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy: a comprehensive review [0.03%]
新辅助放化疗后局部晚期直肠癌等待观察策略的全面回顾
Peng Huang,Xiaoyue Zhao,Huanhuan Fei et al.
Peng Huang et al.
The conventional treatment for locally advanced rectal cancer (LARC) primarily involves neoadjuvant chemoradiotherapy (nCRT) combined with total mesorectal excision (TME). However, surgery-related complications and long-term functional impa...
The impacts of androgen receptor on treatment response and survival in triple-negative breast cancer treated with neoadjuvant chemotherapy: a single-center retrospective study [0.03%]
雄激素受体影响三阴性乳腺癌新辅助化疗的疗效和预后的单中心回顾分析研究
Seda Karaçam,Mehmet Furkan Sağdıç,Zarife Melda Bulut et al.
Seda Karaçam et al.
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, resulting in limited treatment options. Th...